At Amneal we are committed to forming deep relationships with our customers and business partners as well as creating strong value throughout the supply chain. That’s why we've created this website. Get to know Amneal, as a company, partner, supplier, employer or customer. At amneal.com we provide valuable information about our operations, leaders, products, business principles and more… as well as details on how to get in touch with us.
Welcome to Amneal Pharmaceuticals—generic’s new generation. We encourage you to learn more about our remarkable company. Explore our site.
News and Press
GENERIC EQUIVALENT FOR LOESTRIN® 24 COMING SOON
launch its AB-rated generic for Loestrin® 24 Fe. 75 mg the first week of January 2014.
Amneal’s exclusive First-to-File generic equivalent for this brand will be sold under the name
Lomedia™ 24 Fe. Patients will be able to swallow the pill whole just as they
did with Loestrin® 24 Fe.
AMNEAL ENTERS INTO AGREEMENTS WITH SUBSIDIARIES OF ACTAVIS, INC.
Amneal announced today that it has entered into agreements with subsidiaries of Actavis, Inc. to purchase four generic products for cash consideration. One product is currently marketed in the U.S. by Actavis, two products have Abbreviated New Drug Applications currently awaiting regulatory approval, and one product has been approved but is not currently marketed pursuant to a settlement agreement.
AMNEAL GETS APPROVAL FOR GENERIC SUBOXONE®
Amneal has received FDA approval for one of the first generic versions of Suboxone® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles.